Literature DB >> 10188736

Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts.

S Detre1, J Salter, D M Barnes, S Riddler, M Hills, S R Johnston, C Gillett, R A'Hern, M Dowsett.   

Abstract

Endocrine treatments for human breast cancer have been based largely upon the removal of estrogenic stimuli. The regression of tumors after estrogen deprivation has generally been characterized as being due to reduced proliferation but more recently has been recognized to also involve increased apoptosis. The aim of our experiments was to define the associated changes in certain proliferation- and cell death-related biological parameters after hormone withdrawal from estrogen-dependent MCF-7 xenografts in athymic nude mice using immunohistochemical techniques. The baseline estrogen receptor (ER) level of this MCF-7 xenograft was relatively low (average H score 23) but it was strongly Bcl-2-, PgR- and pS2-positive, indicating the functional integrity of estrogen signaling. Changes in proliferation (Ki-67), apoptosis, ER, progesterone receptor (PgR), cyclin D1, p27kip1, Bcl-2 and Bax expression were assessed during the 2 weeks after estrogen deprivation. ER levels rose markedly after estrogen ablation, whereas PgR levels fell to about 10% of baseline and pS2 levels halved. The proportion of Ki-67-positive cells was unchanged after 24 hr but by day 14 had reduced by about 80%. The normal levels of cyclin D1 also reduced after estrogen withdrawal in contrast to the rapid increase in levels of cyclin-dependent kinase inhibitor p27kip1. This latter increase appeared to occur in advance of the changes in Ki-67. The proportion of apoptotic cells increased from a mean 1.5% at baseline to 2.9% after 3 days and 4.7% after 14 days. There were reductions in both Bcl-2 and Bax staining but these appeared to be greater for Bcl-2, effectively decreasing the Bcl-2/Bax ratio. Our results provide a framework for the use of these parameters as intermediate markers in comparisons of hormonal agents for human breast cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10188736     DOI: 10.1002/(sici)1097-0215(19990412)81:2<309::aid-ijc23>3.0.co;2-s

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  Molecular basis for therapy resistance.

Authors:  Per E Lønning
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

2.  Estrogen opposes the apoptotic effects of bone morphogenetic protein 7 on tissue remodeling.

Authors:  D G Monroe; D F Jin; M M Sanders
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

3.  PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.

Authors:  Robert J Crowder; Chanpheng Phommaly; Yu Tao; Jeremy Hoog; Jingqin Luo; Charles M Perou; Joel S Parker; Melinda A Miller; David G Huntsman; Li Lin; Jacqueline Snider; Sherri R Davies; John A Olson; Mark A Watson; Anthony Saporita; Jason D Weber; Matthew J Ellis
Journal:  Cancer Res       Date:  2009-04-14       Impact factor: 12.701

4.  Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer.

Authors:  A E Ring; I E Smith; S Ashley; L G Fulford; S R Lakhani
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

5.  Apoptosis and autophagy in breast cancer cells following exemestane treatment.

Authors:  Cristina Amaral; Margarida Borges; Soraia Melo; Elisiário Tavares da Silva; Georgina Correia-da-Silva; Natércia Teixeira
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

6.  Vascular endothelial growth factor expression and T-regulatory cells in premenopausal breast cancer.

Authors:  Francesco Recchia; Giampiero Candeloro; Stefano Necozione; Giovambattista Desideri; Alisia Cesta; Laura Recchia; Silvio Rea
Journal:  Oncol Lett       Date:  2013-01-18       Impact factor: 2.967

7.  New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death.

Authors:  Margarida Cepa; Georgina Correia-da-Silva; Elisiário J Tavares da Silva; Fernanda M F Roleira; Margarida Borges; Natércia A Teixeira
Journal:  BMC Cell Biol       Date:  2008-07-24       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.